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Site-Specific Proteolytic Cleavage of the Amino Terminus of
Herpes Simplex Virus Glycoprotein K on Virion
Particles Inhibits Virus Entry䌤
Nithya Jambunathan, Sona Chowdhury, Ramesh Subramanian, Vladimir N. Chouljenko,
Jason D. Walker, and Konstantin G. Kousoulas*
Division of Biotechnology and Molecular Medicine and Department of Pathobiological Sciences,
School of Veterinary Medicine, Louisiana State University, Baton Rouge, Louisiana

Herpes simplex virus 1 (HSV-1) glycoprotein K (gK) is expressed on virions and functions in entry,
inasmuch as HSV-1(KOS) virions devoid of gK enter cells substantially slower than is the case for the parental
KOS virus (T. P. Foster, G. V. Rybachuk, and K. G. Kousoulas, J. Virol. 75:12431–12438, 2001). Deletion of the
amino-terminal 68-amino-acid (aa) portion of gK caused a reduction in efficiency and kinetics of virus entry
similar to that of the gK-null virus in comparison to the HSV-1(F) parental virus. The UL20 membrane protein
and gK were readily detected on double-gradient-purified virion preparations. Immuno-electron microscopy
confirmed the presence of gK and UL20 on purified virions. Coimmunoprecipitation experiments using
purified virions revealed that gK interacted with UL20, as has been shown in virus-infected cells (T. P. Foster,
V. N. Chouljenko, and K. G. Kousoulas, J. Virol. 82:6310–6323, 2008). Scanning of the HSV-1(F) viral genome
revealed the presence of a single putative tobacco etch virus (TEV) protease site within gD, while additional
TEV predicted sites were found within the UL5 (helicase-primase helicase subunit), UL23 (thymidine kinase),
UL25 (DNA packaging tegument protein), and UL52 (helicase-primase primase subunit) proteins. The recombinant virus gD⌬TEV was engineered to eliminate the single predicted gD TEV protease site without
appreciably affecting its replication characteristics. The mutant virus gK-V5-TEV was subsequently constructed by insertion of a gene sequence encoding a V5 epitope tag in frame with the TEV protease site
immediately after gK amino acid 68. The gK-V5-TEV, R-gK-V5-TEV (revertant virus), and gD⌬TEV viruses
exhibited similar plaque morphologies and replication characteristics. Treatment of the gK-V5-TEV virions
with TEV protease caused approximately 32 to 34% reduction of virus entry, while treatment of gD⌬TEV
virions caused slightly increased virus entry. These results provide direct evidence that the gK and UL20
proteins, which are genetically and functionally linked to gB-mediated virus-induced cell fusion, are structural
components of virions and function in virus entry. Site-specific cleavage of viral glycoproteins on mature and
fully infectious virions utilizing unique protease sites may serve as a generalizable method of uncoupling the
roles of viral glycoproteins in virus entry and virion assembly.
Membrane fusion phenomena are of paramount importance
in the infectious life cycle of herpes simplex virus 1 (HSV-1).
HSV-1 enters cells predominantly via fusion of its viral envelope with cellular plasma membranes in a pH-independent
manner. An alternative pathway involves receptor-mediated
endocytosis and fusion of the viral envelope with endocytic
membranes facilitated by the low-pH environment of endosomes (30). The virus can spread from infected to uninfected
cells by causing virus-induced cell fusion, allowing virions to
enter uninfected cells without being exposed to extracellular
spaces. These membrane fusion phenomena are known to be
mediated by viral glycoproteins embedded in the viral envelope and expressed on infected cellular plasma membranes
(reviewed in reference 33).
Virus entry into susceptible cells involves the coordinated
functions of glycoproteins gD, gB, gH, and gL (3, 8, 21, 25),
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while a fifth glycoprotein, gC, is known to enhance initial
binding of the virus to cellular membranes (20). The virion
glycoproteins gB and gC bind to glycosaminoglycan (GAG)
moieties of cell surface proteoglycans (20, 36). This initial
attachment of virions to cellular membranes is thought to facilitate subsequent interaction of gD with one or more of its
specific receptors, including the herpesvirus entry mediator
(HVEM, or HveA), nectin-1 (HveC), or 3-O-sulfated heparan
sulfate (17, 27, 35). Apparently, gB can also bind to additional
receptors, including paired immunoglobulin-like type 2 receptor alpha (PILR-␣), nonmuscle myosin heavy chain IIA
(NMHC-IIA), and myelin-associated glycoprotein (MAG),
that function in virion attachment and virus entry (1, 34, 38).
Recent data support the hypothesis that gB is the sole fusion
glycoprotein, since it is the only glycoprotein that possesses
features of other known viral fusion glycoproteins, such as the
well-characterized vesicular stomatitis virus (VSV) G glycoprotein (19, 32). Virus-induced cell fusion is thought to be
mediated by a mechanism very similar to that occurring during
fusion of the viral envelope with cellular membranes, inasmuch
as the viral glycoproteins gD, gB, gH, and gL and the presence
of viral receptors are also required for virus-induced cell fusion
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(2, 31, 40, 41). However, virus-induced cell fusion requires the
presence of additional viral glycoproteins and membrane proteins, including gE, gI, gM, gK, and the UL20 and UL45
proteins (5, 7, 12, 18, 26, 43).
We reported that gK is a structural component of virions as
a Golgi complex-dependent glycosylated species and functions
in virus entry, inasmuch as virions lacking gK enter susceptible
cells in cell culture substantially slower (15). Furthermore, we
showed that HSV-1 gK and UL20 functionally and physically
interact and that these interactions are absolutely necessary for
their coordinate intracellular transport, cell surface expression,
and functions in the HSV-1 life cycle (10, 14). Recently, we
showed that a peptide composed of the amino-terminal 82
amino acids (aa) (including the predicted 30-aa signal sequence) of gK (gKa) complemented in trans for gB-mediated
cell fusion (5). In addition, we demonstrated that UL20 and
the gKa peptide physically interacted with gB and gH in infected cells, suggesting that gB-mediated virus-induced cell fusion
is regulated via direct interactions with gK and UL20 (6).
In this work, we sought to confirm the presence of gK on
purified virion particles and to assess whether the UL20 protein is also a structural component of virion particles in association with gK and function in virus entry. A substantial difficulty in assessing the role of gK in virus entry is the fact that
a lack of gK leads to drastic defects in cytoplasmic virion
envelopment and infectious virus production (11, 22, 23). We
present here a generalizable strategy to modify/inactivate gK
or potentially any other viral glycoprotein on mature virion
particles, effectively uncoupling the roles of gK in cytoplasmic
virion envelopment and virus entry.
MATERIALS AND METHODS
Cell culture. African green monkey kidney (Vero) cells were obtained from
the American Type Culture Collection (Rockville, MD). VK302 cells permanently expressing gK were originally obtained from David Johnson (Oregon
Health Sciences University, Portland, OR). Cells were maintained in Dulbecco’s
modified Eagle’s medium (DMEM) (Gibco-BRL, Grand Island, NY) supplemented with 10% fetal calf serum and antibiotics.
Bioinformatics analysis of predicted protease sites within HSV-1 proteins.
The ExPASy PeptideCutter software tool (16), available at the ExPASy Bioinformatics Resource portal (http://web.expasy.org/peptide_cutter/), was utilized
to predict potential tobacco etch virus (TEV) cleavage sites within each predicted amino acid sequence of the HSV-1(F) genome (GenBank accession number GU734771). The PeptideCutter algorithm predicted the presence of a single
putative TEV site within gD at amino acid 235, while additional TEV predicted
sites were found within the UL5 (helicase-primase helicase subunit; single TEV
predicted site at amino acid 466), UL23 (thymidine kinase; two TEV predicted
sites at amino acid 250 and 331), UL25 (DNA packaging tegument protein; one
TEV site at amino acid 533), and UL52 (helicase-primase primase subunit; one
TEV site at amino acid 184). Treatment of purified virions will access only
structural envelope proteins, such as gD, and not any of the other nonstructural
viral proteins containing TEV sites.
Construction of HSV-1 recombinant mutants. The recombinant mutant
YE102-VC1 was engineered to express gK and UL20 containing the V5 and
3⫻FLAG antigenic epitopes, respectively. Specifically, a DNA sequence encoding the V5 epitope and the enterokinase recognition site, Asp-Asp-Asp-Asp-Lys,
was inserted in frame immediately after amino acid 68 of gK (including the
predicted 30-aa signal sequence). The 3⫻FLAG epitope was inserted in frame at
the amino terminal of UL20, as described earlier (24). All recombinant viruses
were constructed using the markerless two-step red-mediated recombination
mutagenesis system (42) on the bacterial artificial chromosome (BAC) plasmid
pYEbac102 carrying the HSV-1(F) genome or the BAC plasmid pYK608 carrying the HSV-1(F) genome modified to express three fluorescent proteins as
fusion proteins with gB, VP22, and VP26 (gifts from Yasushi Kawaguchi, University of Tokyo, Tokyo, Japan). The mutant virus gD⌬TEV was constructed by
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altering the DNA sequence within the gD gene predicted to specify a TEV
protease recognition site on the bacterial artificial chromosome YK608 genome.
Specifically, gD amino acid 235 was changed from glutamine to asparagine (Fig.
1). The gD⌬TEV virus was subsequently used to generate the gK-V5-TEV
recombinant virus, which expressed gK containing the V5 epitope and the TEV
protease recognition site ENLYFQG inserted in frame immediately after amino
acid 68 of gK.
Virus entry assay. The construction and characterization of the gK mutant
virus gK⌬31-68 lacking 68 aa from its amino terminus (including the 30-aa signal
sequence) was recently described (5). The relative entry efficiencies of the wildtype HSV-1(F) YE102, gK-null (⌬gK), and gK⌬31-68 viruses were tested on
Vero cells by determining the number of cells expressing viral antigens after
entry was allowed to occur for 1 h at 34°C. Specifically, viruses at a multiplicity
of infection (MOI) of 1 were allowed to attach to Vero cell monolayers at 4°C for
1 h. The virus inoculum was subsequently removed, warm medium (34°C) was
added, and the cultures were shifted to 34°C to allow virus penetration. After 1 h
at 34°C, extracellular virions were inactivated by treatment with low-pH buffer
(0.1 M glycine, pH 3.0), and cells were washed three times with phosphatebuffered saline (PBS). Twelve hours postinfection (hpi), the cells were fixed and
stained with anti-ICP4 antibody (Virusys, Inc., Taneytown, MD). The relative
efficiency of virus entry was calculated as the percentage of cells expressing ICP4
after low-pH treatment relative to results for PBS-treated cells by flow cytometry.
Mean values and standard deviations of three independent experiments were
calculated. Similarly, kinetics of virus entry were determined at 34°C by measuring the number of ICP4-positive Vero cells by flow cytometry at 12 hpi. The
percent positive cells for each time point (10, 20, 30, and 60 min) was determined
for a total number of 5,000 Vero cells infected at an MOI of 1.
Growth kinetics and plaque morphology of wild-type and mutant viruses.
Growth kinetics studies were performed essentially as we have described earlier
(11, 13, 15). Briefly, viruses were adsorbed onto a 90%-confluent monolayer of
Vero cells in a 12-well plate at 4°C for 1 h at a low multiplicity of infection
(MOI ⫽ 0.2). Subsequently, cells were incubated at 37°C and 5% CO2 for 1 h to
allow penetration of the virus. Any remaining extracellular virions were inactivated by briefly treating the cells with PBS at low pH (pH 3.0). Virus stocks were
prepared from infected cells at 6, 12, 24, 36, and 48 hpi, and the virus titers
were obtained by endpoint titration on Vero cell in triplicate. Viral plaques were
stained using anti-HSV-1 polyclonal antibody, as described previously (5). Viral
plaques were also visualized by fluorescence microscopy.
Virus entry kinetics of TEV protease-treated virions. Partially purified virions
(generated by concentrating viruses by ultracentrifugation of infected cell supernatants) were used for enzyme digestion studies. Equal PFU of recombinant
mutant viruses gD⌬TEV and gK-V5-TEV were treated as follows: (i) PBS alone
(all PBS used for these experiments was at pH 6.8), (ii) PBS plus 1 unit of
AcTEV protease (Invitrogen, Inc., Carlsbad, CA), and (iii) PBS plus 0.01%
SDS-inactivated AcTEV protease. SDS-inactivated enzyme was passed through
Zeba spin desalting columns (Thermo Fisher Scientific, Waltham, MA) to eliminate SDS. All treatments were kept at 30°C for 1 h, mixed with serum-free
medium, and adsorbed to a 90%-confluent monolayer of Vero cells on a 12-well
plate. The plates were rocked gently for 1 h at room temperature. The virus
inoculum was removed, and the wells were overlaid with 1 ml of DMEM containing 1% methylcellulose and 2% fetal bovine serum (FBS). Cells were fixed at
48 hpi with ice-cold methanol for 10 min, and immunocytochemistry was performed as described above. The effect of TEV protease treatment on the kinetics
of virus entry was performed essentially as described earlier, with the exception
that viruses were treated with TEV protease or PBS and that the number of
infectious virions was determined via limited dilution on Vero cells, as described
previously (15).
TEV digestion of infected cell extracts and immunoblot assays. Nearly confluent monolayers of Vero cells in a T-75 flask were infected with gK-V5-TEV
virus. The cells were collected 48 hpi and lysed with mammalian protein extraction reagent (M-PER; Pierce, Rockford, IL) lysis buffer containing protease
inhibitors and briefly sonicated. The gK-V5-TEV protein was immunoprecipitated with protein G magnetic beads bound to V5 antibody (Invitrogen, Carlsbad, CA). The eluted protein was treated with the AcTEV protease as suggested
by the manufacturer (Invitrogen). Sample buffer containing 5% ␤-mercaptoethanol was added to the digested protein and heated at 55°C for 15 min. Proteins
were resolved on 4 to 20% SDS-PAGE gel and immobilized on nitrocellulose
membranes. Immunoblot assays were carried out using mouse anti-V5 antibody
and goat anti-mouse horseradish peroxidase (HRP) light-chain secondary antibody (Abcam, Inc., Cambridge, MA).
Virus purification. Wild-type HSV-1(F) pYEbac102 and double-labeled
YE102-VC1 (gK-EK-V5; UL20-3⫻FLAG) virions were purified by two serial
passages using iodixanol gradients. Briefly, supernatants and cells from 24 T-150
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FIG. 1. Schematic representation of mutant viral genomes. (A) HSV-1(F)-YE102-VC1 recombinant virus generated from pYEbac102, carrying
an in-frame insertion of the V5 epitope and enterokinase recognition site inserted immediately after amino acid 68 of gK, as well as an in-frame
insertion of the 3⫻FLAG epitope at the amino terminus of UL20. (B) Schematic representation of recombinant viruses constructed for
TEV-specific proteolytic activity. The V5 epitope tag and the TEV protease site (ENLYFQG) were inserted immediately after amino acid 68 of
gK to generate mutant virus gK-V5-TEV.

flasks of Vero cells infected with either pYEbac102 or YE102-VC1 were collected at 24 and 36 hpi, respectively, and treated with TNE (10 mM Tris; 500 mM
NaCl; 1 mM EDTA; pH 7.5) buffer for 15 min at 4°C. Subsequently, the cell
pellet was separated by centrifugation at 6,000 ⫻ g for 45 min at 4°C. Polyethylene glycol (PEG) (molecular weight, 8,000; 7% [wt/vol]) was added to the
supernatant and kept on a stirrer overnight at 4°C. The next day, this solution was
spun at 6,000 ⫻ g for 30 min at 4°C. The resulting pellet was resuspended in 10
ml of TNE buffer, loaded onto a 50 to 20% discontinuous iodixanol gradient, and
spun at 141,000 ⫻ g for 3 h. The viral band from the 30 to 40% interface was
collected, loaded onto a second 50 to 20% iodixanol step gradient, and centrifuged again at 141,000 ⫻ g for 3 h at 4°C. The resulting optically dense band was
centrifuged through a 20% iodixanol cushion at 141,000 ⫻ g for 1 h at 4°C. The
resulting pellet was resuspended in 250 l of NP-40 lysis buffer (Invitrogen) and
used for immunoprecipitation and immunoblot assays.
Immunoprecipitation and immunoblot assays. The gK-V5-EK (gK tagged
with V5 and enterokinase amino acid sequence) protein was immunoprecipitated
with protein G magnetic Dynabeads bound to V5 antibody according to the
manufacturer’s instructions (Invitrogen). The protein was eluted from the magnetic beads in 40 l of elution buffer and used for immunoblot assays. Immunoblot assays were carried out using anti-glyceraldehyde-3-phosphate-dehydrogenase (anti-GAPDH) (Chemicon, International Inc.), anti-gB, anti-gD, anti-gC
(Virusys), anti-FLAG (Sigma-Aldrich, Inc., St. Louis, MO), anti-V5 antibody
(Invitrogen), goat anti-mouse HRP against light-chain (Fab), heavy chain (Fc)
whole mouse IgG molecule (Abcam), and anti-ICP8 monoclonal antibody (Abcam).
Immunogold labeling for TEM. Semipurified virions immobilized on 400-mesh
Butvar/carbon-coated nickel grids (Electron Microscopy Sciences, Inc., Hatfield,
PA) were used to detect the presence of gK, gB, and UL20 on the virions using
immunogold labeling, as has been described previously for bovine herpesvirus 1
(37). Briefly, 5 l of semipurified virions suspension was adsorbed onto the
coated surface of the grids for 30 min. The grids were then blocked using 1%

bovine serum albumin (BSA) in Tris-buffered saline (TBS) for 5 min. Excess
blocking buffer was removed using the tip of a filter paper, followed by incubation of the grids with 5 l of mouse anti-V5 antibody (Invitrogen) at a dilution
of 1:10,000 in 1% BSA in TBS for 30 min. This sample preparation step was
followed by washing the grids with 1% BSA in TBS for 5 min. A 5-l droplet of
goat anti-mouse IgG (whole molecule)-Gold 10-nm colloidal gold (Sigma-Aldrich) at 1:80 dilution in 1% BSA in TBS was added on top of each grid and
incubated for 30 min. The grids were then washed with 1% BSA in TBS by
adding 5 l on each grid, and excess liquid was removed with the tip of a filter
paper. A 2% solution of sodium phosphotungstate, pH 6.8, was added as a final
step for contrast purposes. Grids were desiccated and visualized by transmission
electron microscopy (TEM).

RESULTS
The UL20 membrane protein and gK are structural components of HSV-1 virions. To assess whether both gK and UL20
are present and interact as structural components of HSV-1
virions, the recombinant virus HSV-1(F)-YE102-VC1 was constructed by modifying the gK and UL20 amino acid sequences
to contain V5 and 3⫻FLAG antigenic epitopes, respectively
(Fig. 1A). The V5 epitope tag was inserted immediately after
gK amino acid 68 (this amino acid numbering includes the
predicted signal sequence), while the 3⫻FLAG epitope was
inserted at the N terminus of the UL20 protein, as described
previously for similar gene constructions (9, 10, 14) and detailed in Materials and Methods. The YE102-VC1 virus repli-
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FIG. 2. Replication kinetics and plaque morphology of the
YE102-VC1 virus in comparison to those of HSV-1(F)-YE102.
(A) Representative viral plaques of HSV-1(F)-YE102 and HSV1(F)-YE102-VC1 on Vero cells at 48 hpi. Viral plaques were visualized by phase-contrast microscopy after immunostaining with
anti-HSV-1 polyclonal antibody. (B) One-step replication kinetics
of HSV-1(F)-YE102 and HSV-1(F)-YE102-VC1 at an MOI of 0.2
on Vero cells. The x axis shows hours postinfection, and the y axis
shows PFU/ml. All experiments were performed in triplicate. Error
bars represent standard errors of the means.

cated efficiently in Vero cells; however, average plaque sizes
were consistently smaller, by approximately 30%, than those of
the parental HSV-1(F)-YE102 virus (Fig. 2A). Similarly,
YE102-VC1 replicated slower than the YE102 parental virus,
approaching viral titers that were approximately half a log
lower than YE102 at 24 hpi (Fig. 2B). However, at longer times
postinfection (36 to 48 hpi), titers of both viruses were similar
(not shown).
YE102-VC1 virions were purified by sequential isopycnic
density sedimentation in iodixanol discontinuous gradients as
described in Materials and Methods. The cellular protein
GAPDH was absent from gradient fractions containing infectious virions, indicating the relative absence of contaminating
cellular proteins, while GAPDH was readily detected in control cellular extracts (Fig. 3, panel labeled ␣-GAPDH). Similarly, the nonstructural, immediate-early protein ICP8 was not
detected in purified virion samples, while it was detected readily in samples obtained from infected cells (Fig. 3, panel labeled ␣-ICP8). Purified virions were tested for the presence of
the viral glycoproteins gB, gD, gC, and gK and the membrane
protein UL20 using monoclonal antibodies against gB, gD, gC,
anti-V5 (gK), and anti-3⫻FLAG (UL20) in Western immunoblots. Monoclonal antibody to gB detected putative mature gB
protein species migrating with an apparent molecular mass of
approximately 120 kDa, while a relatively prominent gB-related species of approximately 45 kDa was also detected (Fig.
3, panel labeled ␣-gB). Monoclonal antibody to gD detected a
single protein species migrating with an apparent molecular
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FIG. 3. Detection of gK and UL20 on gradient-purified virions.
Western immunoblot analysis of double-gradient-purified virions was
performed using anti-V5 (gK) and anti-FLAG (UL20) antibodies.
Individual lanes are labeled as follows: C, positive control for GAPDH;
W, lysates from purified wild-type virus [HSV-1(F)-YE102]; M, lysates
from purified mutant virus YE102-VC1; L, lysates from infected Vero
cells; V, samples derived from purified virions. Individual blots were
probed with anti-GAPDH, anti-ICP8, anti-gB, anti-gD, anti-gC, antiFLAG (UL20), or anti-V5 (gK) antibody as indicated. The panel
labeled at the top as IP:V5Ab shows immunoblots of immunoprecipitations with anti-V5 (gK) antibody probed with either anti-FLAG
(UL20) or anti-V5 (gK) antibodies. In this panel, lanes are immunoprecipitates from mock-infected Vero cells (U), HSV-1(F)-YE102 purified virions (W), or YE102-VC1 purified virions (M). Molecular mass
standards are shown with dots on each panel (250, 150, 100, 75, 50, 37,
25, 20, 15, and 10 kDa; Precision Plus protein standards; Bio-Rad).
HRP-conjugated goat anti-mouse (HRP-GAb; IgG) was used for all
data, except data shown on the panel labeled IP:V5Ab, wherein the
F(ab)2- and Fc-purified portions of the HRP-GAb IgG were used for
the ␣-V5 and ␣-FLAG panels, respectively.

mass of approximately 55 kDa (Fig. 3, panel labeled ␣-gD),
while antibody to gC detected a protein with an apparent
molecular mass of 125 kDa. Anti-3⫻FLAG antibody readily
detected the presence of the UL20 protein migrating with a
characteristic ladder pattern, with the most prominent protein
species migrating with an apparent molecular mass of approximately 27 kDa, in agreement with our previous findings (6), as
well as UL20-associated protein species migrating with apparent molecular masses of approximately 35 and 45 kDa (Fig. 3,
panel ␣-FLAG). The anti-V5 antibody detected the presence
of the V5-tagged gK-associated protein species migrating with
an apparent molecular mass of approximately 65 to 75 kDa,
which was more than twice the apparent molecular mass of
glycosylated species of gK previously detected in infected cells
(5, 6). The anti-V5 (gK) antibody immunoprecipitated gK migrating with an apparent molecular mass of 125 kDa and coimmunoprecipitated UL20 migrating at approximately 27 kDa,
which was detected with the anti-3⫻FLAG antibody (Fig. 3,
panel labeled IP:V5Ab).
The presence of gK on virion particles was further assessed
using colloidal gold immuno-electron microscopy (Fig. 4).
More than 100 virion particles for each virus were visually
scanned for the presence of gold particles. V5-tagged gK was
readily detected on most virion envelopes (⬎90 out of 100
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visualized virions contained gold particles) of recombinant viruses VC1 and gK-V5-TEV, both of which contained the V5
epitope tag inserted after gK amino acid 68 (Fig. 4B and C),
while the antibody did not react with the VC1 parental virus
YE102 (none of 100 visualized virions contained gold particles) (Fig. 4A). Similarly, anti-gB monoclonal antibody readily
detected gB on most visualized virions (not shown).
The amino terminus of gK functions in virus entry. Previously, we reported that deletion of 68 aa from the amino
terminus of gK (including the 30-aa signal sequence; actual
deletion of 38 aa after cleavage of the predicted signal sequence) allowed efficient virus envelopment and infectious virus production, while gB-mediated virus-induced cell fusion
was abolished (5). The entry efficiency of the recombinant virus
gK⌬31-68, which lacks the first 68 aa of gK, was compared to
those of HSV-1(F; YE102) and ⌬gK viruses. The construction
and characterization of these viruses have been described previously (5). Flow cytometry was utilized to determine the relative efficiencies and kinetics of entry of these viruses into
Vero cells (see Materials and Methods). Both ⌬gK and
gK⌬31-68 entered Vero cells less efficiently than their parental
virus, YE102 (Fig. 5A and B).
To further confirm that deletion of the amino-terminal 68 aa
of gK caused defects in virus entry, we utilized incorporation of
a unique TEV protease site within gK to selectively delete the
amino terminus of gK from mature virions. Scanning of the
HSV-1(F) viral genome revealed the presence of a single putative TEV site within gD, while additional TEV predicted
sites were found within the UL5 (helicase-primase helicase
subunit), UL23 (thymidine kinase), UL25 (DNA packaging
tegument protein), and UL52 (helicase-primase primase subunit) (see Materials and Methods). The recombinant virus
gD⌬TEV was constructed via site-directed mutagenesis of the
YK608 genome, changing the single putative gDTEV site from
PQAYQQG to PQAYQNG (Q235 to N235; bold and underlined). Subsequently, the recombinant virus gK-V5-TEV was
constructed by inserting a 19-aa gene segment coding for the
V5 epitope tag fused in frame with the predicted TEV protease
site (ENLYFQG), inserted immediately after gK amino acid
68. Both gD⌬TEV and gK-V5-TEV viruses produced averagesize plaques that were approximately 30% smaller than those
of the YK608 parental virus at 48 hpi, while all viruses ex-

FIG. 5. Assessment of the efficiencies of gK-null and gK⌬31–68 virus
entry into Vero cells. (A) The relative efficiency of entry is shown as the
percentage of cells expressing ICP4 at 12 hpi. Mean values and standard
deviations for three independent experiments were calculated as shown.
(B) Representative kinetics of virus HSV-1(F), gK-null, and gK⌬31-68
entry into Vero cells. Vero cell monolayers were infected with an MOI of
1. At different times postentry at 34°C (10, 20, 30, and 60 min), viruses that
had not entered yet were inactivated with low pH, and the kinetics of virus
entry were determined by monitoring ICP4 expression at 12 hpi using flow
cytometry. For each sample, the percent ICP4-positive cells in a population of 5,000 Vero cells was measured.
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FIG. 4. Transmission immunogold electron microscopy to detect gK and gB on virion particles. (A) HSV-1(F)-YE102 virions stained with
anti-gK (anti-V5) antibody; (B) YE102-VC1 stained with anti-gK (anti-V5) antibody; (C) gK-V5-TEV stained with anti-gK (anti-V5) antibody.
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FIG. 6. Construction and characterization of recombinant viruses containing TEV modifications. (A) Representative plaque morphology of the
gD⌬TEV and gK-V5-TEV viruses in comparison to those of their parental HSV-1(F)-YK608 virus at 48 hpi. Viral plaques were visualized after
immunohistochemical staining using phase-contrast microscopy and by fluorescence microscopy. (B) Replication kinetics of HSV-1(F) YK608,
gD⌬TEV, and gK-V5-TEV viruses on Vero cells infected with an MOI of 0.2. The x axis shows hours postinfection, and the y axis shows PFU/ml.
All experiments were performed in triplicate. Error bars represent standard errors of the means.

pressed the characteristic fluorescence pattern of green, red,
and cyan due to fluorescent proteins fused in frame to the
VP26, VP22, and gB viral proteins, respectively (Fig. 6A) (39).
The gD⌬TEV and gK-V5-TEV viruses replicated efficiently,
although slower in Vero cells than was the case for their parental wild-type virus, YK608, while the two mutant viruses
approached similar viral titers at 48 hpi (Fig. 6B). A gK-V5TEV revertant (R-gK-V5-TEV) virus was generated by replacing the gK-V5-TEV gene with the wild-type HSV-1(F) gK gene
using two-step red-mediated recombination mutagenesis. The
R-gK-V5-TEV virus exhibited plaque morphology and growth
characteristics similar to those of the gD⌬TEV virus, suggesting that gK-V5-TEV did not contain any secondary site mutations (not shown).
To ascertain whether the TEV protease was active against
the gK-V5-TEV tagged protein, immunoprecipitates of gK
prepared from gK-V5-TEV virus-infected cells were treated
with the TEV protease as described in Materials and Methods.
Treatment of cellular extracts with the TEV protease caused a
substantial reduction in the amount of mature gK migrating
with the expected molecular mass of approximately 40 kDa in
comparison to results for phosphate-buffered saline (PBS)-

treated samples. In contrast, inactivated TEV protease failed
to reduce the amount of mature gK (Fig. 7A and B).
To assess whether TEV treatment of recombinant viruses
affected virus entry, partially purified and concentrated virion
stocks were treated with the TEV protease and viral infectivity
was assessed by determining the number of PFU produced
after TEV treatment on Vero cells, as described in Materials
and Methods. TEV treatment of gK-V5-TEV virions resulted
in a 34% or 32% reduction in virus infectivity compared to
results for treatment with inactivated TEV protease or PBS
(respectively) (Fig. 8A and B). This reduction in virus entry can
be appreciated even more when compared to results for TEV
treatment of gD⌬TEV, which appeared to be modestly protected after TEV treatment, exhibiting a 14% or 10% increase
in viral infectivity compared to inactivated TEV protease or
PBS treatment, respectively. Similar results were obtained
when kinetics of viral entry were obtained by inactivating virion
remaining on the cell surface at different times using the
low-pH inactivation protocol (see Materials and Methods).
TEV treatment resulted in a consistent reduction of gK-V5TEV virion entry at different time points, while it did not have
any appreciable effect on gD⌬TEV virion entry (Fig. 8C and D).
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FIG. 8. The effect of TEV protease treatment on virion infectivity. gD⌬TEV (A) or gK-V5-TEV (B) virus obtained from supernatants of
infected cells was treated with PBS, AcTEV protease (PBS ⫹ E), or SDS-inactivated AcTEV protease [PBS ⫹ INACT.E (CP)], and the numbers
of resultant PFU were determined. Similarly, the relative kinetics of viral entry were determined for gD⌬TEV (C) or gK-V5-TEV (D) in the
presence (PBS ⫹ E) or absence (PBS) of the AcTEV protease. These experiments were done in triplicate, and error bars represent standard errors
of the means. Asterisks in panel B designate statistically significant differences as calculated by one-way analysis of variance (ANOVA) (P ⬍ 0.05).
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FIG. 7. Treatment of infected cell extracts. (A) Cell extracts from
gK-V5-TEV-infected cells were immunoprecipitated with anti-V5 antibody and mock or TEV treated for 1 h at 30°C. Immunoprecipitates
were tested for the presence of gK using anti-V5 antibody. Lane 1
(PBS), cell extracts mock digested in PBS buffer; lane 2 (PBS ⫹ E), cell
extracts digested with AcTEV in PBS; lane 3 [PBS ⫹ INACT.E (CP)],
PBS plus inactivated enzyme passed through a desalting column; lane
4 [PBS ⫹ E (CP)], PBS plus enzyme passed through a desalting
column. (B) Densitometric analysis of immunoblots shown in panel A.

HSV-1 enters by fusion of the viral envelope with cellular
membranes and can spread from infected to uninfected cells
via virus-induced cell fusion. Both membrane fusion phenomena are thought to be mediated by similar mechanisms involving glycoprotein gB as the sole fusogen, which is regulated by
interactions with other viral glycoproteins, membrane proteins,
and cellular receptors. Viral glycoproteins and membrane proteins, including gK, gM, gE, gI, and the UL20 membrane
protein, have been cast as nonessential for virus entry, while it
is largely accepted that they are absolutely essential for virusinduced cell fusion. We report here that both gK and UL20 are
structural components of the virion particle and interact with
each other, as has been found in infected cellular membranes.
Furthermore, we utilized protease-specific cleavage of gK on
the mature virion particle to demonstrate that the amino terminus of gK functions in virus entry, in agreement with its role
in virus-induced cell fusion (5).
We have shown previously that both gK and UL20 can be
modified via insertion of small antigenic epitope tags without
drastically affecting their structure and functions in the life
cycle of the virus (9, 15). To confirm the presence of gK and
detect UL20 on purified virions, the recombinant virus YE102-
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VC1 was constructed to express gK tagged with the V5 amino
acid sequence immediately followed by a 5-aa sequence predicted to be a cleavage site of the enterokinase protease. This
19-aa sequence was inserted in frame after gK amino acid 68
(threonine), while the previously reported V5-alone insertion
was immediately after amino acid 69 (histidine) (9). The
YE102-VC1 virus was also modified to include a 3⫻FLAG
epitope tag at the amino terminus of UL20, as described previously (10, 14). The VC-1 virus replicated less efficiently in
Vero cells and formed smaller plaques than its parental virus,
YE102, suggesting that the presence of both gK and UL20
modifications only mildly inhibited virus growth and spread.
VC-1 replication and plaque morphology were partially complemented on either gK-expressing VK302 cells or UL20-expressing FRT cells, suggesting that both gK and UL20 modifications were responsible for the mild reduction in infectious
virus production and virus spread exhibited by the YE102-VC1
virus (not shown).
UL20 and gK were detected on highly purified virions, as
evidenced by the absence of the cellular protein GAPDH and
the nonstructural ICP8 viral protein. V5 (gK) antibody immunoprecipitates probed with either anti-V5 antibody or antiFLAG (UL20) antibodies revealed the presence of UL20 and
gK of approximately 27 kDa and 125 kDa, respectively. This
125-kDa apparent molecular mass of gK was much larger than
the monomeric form of gK (37 kDa), although potentially
dimeric gK protein species of approximately 65 kDa have been
detected previously in infected cells (10). These results suggest
that UL20 interacted predominantly with multimeric (tetrameric) forms of gK in the virion particle. These multimeric
forms of gK were probably not readily detected in infected cell
lysates because they could not enter gels in the presence of
other cellular proteins. Both gK and UL20 are very sensitive to
temperature-dependent aggregation, and samples containing
gK and/or UL20 cannot be boiled because they form aggregates that do not enter separating gels. The larger amount of
total protein present in gK and UL20 samples obtained from
infected cells exacerbates this phenomenon (unpublished observations). The presence of gK on purified virions was confirmed using transmission immuno-electron microscopy. The
UL20 protein was also readily detected on virions by TEM,
although the anti-UL20 antibody was directed against the
amino terminus of UL20, predicted to be located on the inner
side of the viral envelope. This staining was probably due to
partial breakage of virion envelopes that exposed the UL20
epitope to the antibody (not shown). Collectively, these data
support our hypothesis that gK is present in the viral envelope
as an interactive complex with UL20, in agreement with our
previous findings in infected cells (10, 14).
We showed previously that HSV-1(KOS) gK-null virus entered Vero cells substantially slower than its parental KOS
strain (15). Because gK is required for efficient cytoplasmic
virion envelopment and infectious virus production, viral entry
experiments with gK-null viruses reflect the ability of only a
very small portion of potentially aberrantly enveloped virions
to enter cells, substantially complicating interpretation of viral
entry results. Virus entry experiments with the gK⌬31-68 virus,
which carries a deletion of the first 68 aa (38-aa deletion after
the signal sequence of 30 aa) of gK, revealed that it entered
Vero cells substantially less efficiently than the parental virus,
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YE102, confirming that the amino terminus of gK is involved
in virus entry, as has been found for virus-induced cell fusion
(5, 6).
The purpose for engineering the enterokinase site within the
amino terminus of gK was to assess whether treatment with
enterokinase affected virus entry. Unfortunately, enterokinase
treatment of virions did not affect virus entry. Optimum enterokinase protease activity required prolonged incubation at
37°C in the presence of detergent, which was incompatible with
the use of this enzyme in virus entry experiments (not shown).
As an alternative strategy, we chose to construct recombinant
viruses containing TEV protease recognition sites. TEV protease is highly stable at temperatures lower than 37°C and a
wide range of pH (6.0 to 8.0) conditions (29). Scanning of the
HSV-1(F) genome for potential TEV protease sites revealed
the presence of a single putative TEV site within gD among all
viral glycoproteins, while additional sites were located within
the UL5, UL23, UL25, and UL52 genes. The putative TEV
protease site in gD of HSV-1(F) YK608 virus was inactivated
by a single amino acid change, glutamine to asparagine, at
amino acid position 235. The gD amino acid sequence extending from amino acid 234 to 244 was shown to be highly important for infectious virus production (28). Furthermore, insertion of the amino acid segment REDLP at gD amino acid 235
abrogated viral infectivity and resulted in the loss of binding of
monoclonal antibody AP7, which is known to target the discontinuous neutralizing epitope on gD (4). However, the single-amino-acid replacement (glutamine to asparagine) in gD
specified by the gD⌬TEV virus was apparently well tolerated,
since it caused only a modest reduction in the average plaque
size and infectious virus production, suggesting that this amino
acid position does not drastically affect gD functions.
TEV protease treatment of gK-V5-TEV virions resulted in a
more than 30% reduction in virus infectivity compared to results for treatment with either inactivated TEV protease or
PBS. This reduction in virus entry can be appreciated even
more when compared to TEV protease treatment of the parental gD⌬TEV virions, which appeared to slightly enhance
virus entry. The inhibition level of gK-V5-TEV entry after
TEV protease is in agreement with the observed reduction of
gK⌬31-68 virus entry, suggesting that the amino terminus of
gK is contributing to virus entry. We have shown previously
that the amino-terminal 82-aa region of gK binds to the amino
terminus of gB and that this interaction appeared to be important in infectious virus production and virus-induced cell
fusion. Therefore, the observed reduction in virus entry after
cleavage of the amino-terminal 68 aa of gK is consistent with
the hypothesis that this gK peptide may bind gB within the
virion particle and modify its ability to mediate viral-envelopeto-cellular-membrane fusion during virus entry.
The results presented herein provide additional evidence
that gK and its interacting partner UL20 are structural components of the virion particle and function in virus entry. In this
regard, these results support the hypothesis that viral-envelope-to-cell-membrane fusion is similar to virus-induced cell
fusion. It is highly likely that functional interactions among
viral glycoproteins necessary for virus-induced cell fusion are
conserved within the viral envelope, suggesting that deletion of
viral glycoproteins other than gB, gD, gH, and gL may affect
viral entry, as has been shown here for gK. UL20, gK, and
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other membrane proteins embedded in the viral envelope may
function to optimize gB’s fusogenicity for yet-unknown reasons, one of which may be the optimal recognition of various
receptors and entry into different types of cells.
The use of specific protease cleavage sites, such as the TEV
protease site described here, provides a methodology to investigate the role of viral glycoproteins in virus entry independently of their role in virion assembly. In addition, site-specific
cleavage of viral glycoproteins may provide a means of probing
dynamic conformational changes of viral glycoproteins during
virus entry and virus-induced cell fusion.
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